Condition: Breast Cancer · Locally Advanced Breast Cancer · Metastatic Breast Cancer · Sponsor: Olema Pharmaceuticals, Inc.
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
This description comes directly from the study's public registry record.
Olema Pharmaceuticals, Inc. · 415-651-7206 · OPERA-02@olema.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | Hot Springs, Arkansas, United States | Active Not Recruiting |
| Clinical Trial Site | Beverly Hills, California, United States | Active Not Recruiting |
| Clinical Trial Site | La Jolla, California, United States | Active Not Recruiting |
| Clinical Trial Site | Los Alamitos, California, United States | Active Not Recruiting |
| Clinical Trial Site | San Francisco, California, United States | Recruiting |
| Clinical Trial Site | Santa Barbara, California, United States | Active Not Recruiting |
| Clinical Trial Site | Aurora, Colorado, United States | Active Not Recruiting |
| Clinical Trial Site | Denver, Colorado, United States | Recruiting |
| Clinical Trial Site | New Haven, Connecticut, United States | Active Not Recruiting |
| Clinical Trial Site | Tampa, Florida, United States | Recruiting |
| Clinical Trial Site | Marietta, Georgia, United States | Recruiting |
| Clinical Trial Site | Honolulu, Hawaii, United States | Recruiting |
+ 155 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07085767